6-K
Jyong Biotech Ltd. (MENS)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUERPURSUANT TO RULE 13a-16 OR 15d-16UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of January 2026
Commission File Number: 001-42701
Jyong Biotech Ltd.
23F-3, No. 95, Section 1, Xintai 5^th^ Road,Xizhi District, New Taipei City,Taiwan, 221
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
Explanatory Note
Jyong Biotech Ltd, a Cayman Islands exempted company (the “Company”), is hereby furnishing its unaudited interim balance sheet and unaudited interim statement of operations and comprehensive income (loss) for the six months ended June 30, 2025. The condensed consolidated financial statements furnished herein are unaudited and prepared by management of the Company. The financial statements are attached as Exhibit 99.1 to this report of foreign private issuer on Form 6-K.
EXHIBIT INDEX
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Jyong Biotech Ltd. | ||
|---|---|---|
| Date: January 9, 2026 | By: | /s/ Fu-Feng Kuo |
| Name: | Fu-Feng Kuo | |
| Title: | Chief Executive Officer |
2
Exhibit 99.1
JYONG BIOTECH LIMITED
UNAUDITED INTERIM CONDENSED CONSOLIDATED BALANCESHEETS
(in thousand US Dollars, except share and per share data)
| As of<br> <br>June 30,<br> <br>2025 | |||||
|---|---|---|---|---|---|
| Unaudited | |||||
| ASSETS | |||||
| Current Assets | |||||
| Cash | 98 | $ | 132 | ||
| Restricted cash | 3 | 3 | |||
| Short-term investments | - | 16,875 | |||
| Prepayments and other current assets | 105 | 153 | |||
| Total current assets | 206 | 17,163 | |||
| Property and equipment, net | 3,049 | 3,358 | |||
| Operating right-of-use assets | 137 | 94 | |||
| Deferred offering costs | 934 | - | |||
| Restricted asset | 2,034 | 2,049 | |||
| Loan receivable from shareholder | - | 15,000 | |||
| Other non-current assets | 6 | 7 | |||
| Total non-current assets | 6,160 | 20,508 | |||
| TOTAL ASSETS | 6,366 | $ | 37,671 | ||
| LIABILITIES AND SHAREHOLDERS’ DEFICIT | |||||
| Current liabilities | |||||
| Short-term bank loans | 7,225 | $ | 22,436 | ||
| Notes and accounts payable | 3 | 3 | |||
| Accrued expenses | 1,203 | 991 | |||
| Accrued expenses due to related parties | 147 | 219 | |||
| Current portion of long-term bank loans | 57 | 349 | |||
| Operating lease liabilities due to related parties-current | 159 | 131 | |||
| Other current liabilities | 3,292 | 3,366 | |||
| Other current liabilities due to related parties | 41 | 59 | |||
| Total current liabilities | 12,127 | 27,554 | |||
| Long-term loan from related parties | 5,515 | 7,195 | |||
| Long-term loan from third parties | 3,131 | 3,131 | |||
| Long-term bank loans, net of current portion | 2,032 | 1,945 | |||
| Operating lease liabilities due to related parties – non-current | 16 | 7 | |||
| Other non-current liabilities | 58 | 58 | |||
| Other non-current liabilities due to related parties | 628 | 628 | |||
| Guarantee liabilities | 19,378 | 19,625 | |||
| Total non-current liabilities | 30,758 | 32,589 | |||
| TOTAL LIABILITIES | 42,885 | 60,143 | |||
| Commitments and contingencies | |||||
| Shareholders’ deficit | |||||
| Ordinary shares, 0.00001 par value; 5,000,000 thousand shares authorized; 73,361 thousand and 76,028 thousand shares issued and outstanding as of December 31, 2024 and June 30, 2025, respectively | 1 | 1 | |||
| Additional paid-in capital | 11,805 | 28,263 | |||
| Treasury shares, 1,794 thousand shares as of December 31, 2024 and June 30, 2025 | (16,366 | ) | (16,366 | ) | |
| Accumulated deficit | (33,080 | ) | (34,332 | ) | |
| Accumulated other comprehensive income (loss) | 1,121 | (38 | ) | ||
| Total shareholders’ deficit | (36,519 | ) | (22,472 | ) | |
| TOTAL LIABILITIES AND SHAREHOLDERS’ DEFICIT | 6,366 | $ | 37,671 |
All values are in US Dollars.
JYONG BIOTECH LIMITED
UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTSOF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
(in thousand US Dollars, except share data inthousands and per share data)
| For the six months ended<br> <br>June 30, | ||||||
|---|---|---|---|---|---|---|
| 2024 | 2025 | |||||
| Unaudited | Unaudited | |||||
| Operating expenses | ||||||
| Research and development | $ | (499 | ) | $ | (367 | ) |
| Selling and marketing | (21 | ) | (20 | ) | ||
| General and administrative | (431 | ) | (429 | ) | ||
| Total operating expenses | (951 | ) | (816 | ) | ||
| Loss from operations | (951 | ) | (816 | ) | ||
| Other incomes (expenses): | ||||||
| Interest income | 6 | 24 | ||||
| Interest expenses | (448 | ) | (417 | ) | ||
| Other gains (losses), net | 67 | (43 | ) | |||
| Total other expenses, net | (375 | ) | (436 | ) | ||
| Loss before income tax | (1,326 | ) | (1,252 | ) | ||
| Income tax expense | - | - | ||||
| Net loss | (1,326 | ) | (1,252 | ) | ||
| Other comprehensive income (loss) | ||||||
| Foreign currency translation adjustments, net of nil tax | 473 | (1,163 | ) | |||
| Unrealized gain on short term investments, net of nil tax | - | 4 | ||||
| Total other comprehensive income (loss) | 473 | (1,159 | ) | |||
| Total comprehensive loss | $ | (853 | ) | $ | (2,411 | ) |
| Net loss per share: | ||||||
| Basic and Diluted | $ | (0.02 | ) | $ | (0.02 | ) |
| Weighted average shares outstanding (in thousands): | ||||||
| Basic and Diluted | 71,567 | 71,758 |